节点文献

趋化因子受体CXCR4拮抗剂AMD3100的合成及99mTc标记

Synthesis of AMD3100 for antagonist of CXCR4 and labeled with 99mTc

  • 推荐 CAJ下载
  • PDF下载
  • 不支持迅雷等下载工具,请取消加速工具后下载。

【作者】 徐志宏张锦明张晓军田嘉禾

【Author】 HU Zhi-hong,ZHANG Jin-ming,ZHANG Xiao-hui,TIAN Jia-he

【机构】 江苏华益化工有限公司解放军总医院核医学科

【摘要】 趋化因子受体CXCR4在大多数恶性肿瘤中高表达,其小分子拮抗剂AMD3100能用于肿瘤的治疗.AMD3100与金属离子结合后能增加10位的CXCR4的亲和性.本研究以N,N-二(3-氨丙基)乙基乙胺为原料合成了AMD3100,并用放射性金属核素99mTc标记,生物学分布表明:放射性主要分布于高表达的肝组织,荷Hep-G2移植肝癌显像表明,肿瘤明显放射性,说明99mTc-AMD3100是一个有希望的肿瘤CXCR4表达显像剂。

【Abstract】 Most human tumors would be over-express CXCR4.AMD3100,a nonpeptide antagonist for CXCR4 receptor, can be used for therapy those tumors.It was found that metal ion complex,such as Cu2+,with AMD3100 enhanced its binding affinity to the receptor 10-fold higher as compared to AMD3100 alone.AMD3100 was synthesis from 3-aminopropyl ethylene diamine.99mTc-AMD3100 was labeled,and was studied biodistribution in NH mice.The results showed the radioactivity was high at liver which was high-express CXCR4.The SPECT imaging showed that Hep-G2 tumor had high radioactivity uptake in mice.99mTc-AMD3100 was an attractive candidate for further development of SPECT radiotracer potentially suitable for CXCR4.

【关键词】 趋化因子受体CXCR4AMD310099mTc
【Key words】 ChemokinesCXCR4AMD310099mTc
【基金】 国家自然科学基金资助(81771400,81071170)
  • 【会议录名称】 中国核科学技术进展报告(第二卷)——中国核学会2011年学术年会论文集第8册(辐射研究与应用分卷、同位素分卷、核农学分卷)
  • 【会议名称】中国核学会2011年学术年会
  • 【会议时间】2011-10-11
  • 【会议地点】中国贵州贵阳
  • 【分类号】TL923;R914
  • 【主办单位】中国核学会
节点文献中: